BioNTech SE (BNTX)
88.12
-1.56
(-1.73%)
USD |
NASDAQ |
Oct 23, 16:00
88.10
-0.01
(-0.01%)
After-Hours: 20:00
BioNTech Enterprise Value : 5.602B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 5.602B |
| October 22, 2026 | 5.993B |
| October 21, 2026 | 6.400B |
| October 20, 2026 | 6.370B |
| October 19, 2026 | 5.877B |
| October 16, 2026 | 5.500B |
| October 15, 2026 | 6.126B |
| October 14, 2026 | 5.739B |
| October 13, 2026 | 5.827B |
| October 12, 2026 | 7.543B |
| October 09, 2026 | 7.824B |
| October 08, 2026 | 6.593B |
| October 07, 2026 | 7.394B |
| October 06, 2026 | 7.515B |
| October 05, 2026 | 7.995B |
| October 02, 2026 | 7.809B |
| October 01, 2026 | 7.796B |
| September 30, 2026 | 8.161B |
| September 29, 2026 | 8.228B |
| September 28, 2026 | 8.357B |
| September 25, 2026 | 8.216B |
| September 24, 2026 | 8.402B |
| September 23, 2026 | 8.201B |
| September 22, 2026 | 8.806B |
| September 21, 2026 | 8.085B |
| Date | Value |
|---|---|
| September 18, 2026 | 7.598B |
| September 17, 2026 | 8.251B |
| September 16, 2026 | 7.540B |
| September 15, 2026 | 7.756B |
| September 14, 2026 | 8.301B |
| September 11, 2026 | 7.766B |
| September 10, 2026 | 7.683B |
| September 09, 2026 | 8.118B |
| September 08, 2026 | 8.251B |
| September 04, 2026 | 9.532B |
| September 03, 2026 | 9.311B |
| September 02, 2026 | 9.545B |
| September 01, 2026 | 9.076B |
| August 31, 2026 | 8.992B |
| August 28, 2026 | 9.109B |
| August 27, 2026 | 11.45B |
| August 26, 2026 | 11.74B |
| August 25, 2026 | 12.12B |
| August 24, 2026 | 11.81B |
| August 21, 2026 | 12.75B |
| August 20, 2026 | 11.32B |
| August 19, 2026 | 11.88B |
| August 18, 2026 | 6.766B |
| August 17, 2026 | 6.478B |
| August 14, 2026 | 6.852B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| Moderna, Inc. | 75.99B |
| Mereo BioPharma Group Plc | 15.88M |
| NuCana Plc | -20.75M |
| Immatics NV | 566.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -954.35M |
| Revenue (Quarterly) | 122.78M |
| Total Expenses (Quarterly) | 1.077B |
| EPS Diluted (Quarterly) | -3.799 |
| Gross Profit Margin (Quarterly) | -169.3% |
| Profit Margin (Quarterly) | -777.3% |
| Earnings Yield | -8.91% |
| Normalized Earnings Yield | -4.862 |